U.S. Conference on AIDS – Highlights of Day 3
This is the third in our series of daily highlights from the U.S. Conference on AIDS in Chicago. This post spotlights some activities related to treatment and the National HIV/AIDS Strategy (NHAS) from Saturday, November 12. Later this week we will provide a summary of the final day of the conference along with a blog post highlighting new media activities that took place.
Antiretroviral Therapy Discussion
Yesterday’s plenary session featured a discussion of the HIV prevention benefits of antiretroviral therapy (ART) -- also known as combination therapy which involves using a combination of three or more antiretroviral (ARV) drugs from at least two different HIV drug classes to prevent HIV from replicating (read more about ART on NIH’s AIDSinfo site). Dr. Tony Mills, a UCLA HIV physician, discussed new evidence suggesting the potential for ARVs to serve two important new roles in the fight against HIV, in addition to their original function of prolonging health and improving survival among persons living with HIV. These included: 1) reducing the risk of HIV transmission by lowering the infected partner’s viral load with early treatment initiation (known as “treatment as prevention”); and, 2) decreasing the risk of HIV acquisition through pre-exposure prophylaxis (PrEP). Dr. Mills reviewed the implications of HPTN 052, which offers the most definitive evidence that early treatment initiation curbs the risk of HIV transmission in stable, discordant heterosexual couples. He also examined the potential of PrEP for averting new infections, stressing that the research (see posts about the iPrex study) indicates that the level of protection was dependent on adherence to the treatment regimen. He also noted that currently the evidence base for the use of this prevention intervention exists only for men who have sex with men, but that additional studies are underway testing its effectiveness with other populations. He highlighted CDC’s interim guidance on the use of PrEP in men who have sex with men and raised some of the questions the HIV community is facing regarding deploying this intervention such as how will it be administered and by whom? Finally, Dr. Mills highlighted recent revisions to the National Institutes of Health’s HIV Treatment Guidelines, which provide updates on treatment regimens, dosages, and interactions.
Reducing HIV Stigma and Discrimination
An important step in achieving the NHAS goal of reducing HIV-related disparities and health inequities is reducing stigma and discrimination against people living with HIV. During a session on this topic, Ms. Allison Nichol, Chief of the Disability Rights Section of the Department of Justice’s (DOJ) Civil Rights Division, presented on the 2008 amendments of the Americans with Disabilities Act, which define HIV as a covered disability. DOJ now has a one-click system for filing HIV-related discrimination complaints through their website and encourages its use. Ms. Nichol also reported that DOJ has increased its policy work to address the misinterpretation of communicable diseases laws that may result in HIV discrimination. Other speakers from the American Civil Liberties Union, Lambda Legal, and the Center for HIV Law and Policy presented several examples of the persistence of inaccurate information about the mechanisms of HIV transmission in recent discrimination cases.
Increasing Routine HIV Testing in Primary Care
According to the CDC, a New York City-based multi-site federally qualified health center, shared results and lessons from their effort to implement routine HIV testing in a primary care program. Workshop participants acknowledged several challenges to implementing routine testing in primary care settings, including administrative barriers, provider buy-in, patient flow, staff turnover, documentation, and test costs. The presenters outlined how they leverage their existing Electronic Health Records and a quality improvement (QI) processes to support and improve integration of routine HIV testing. In a very short time period and with minimal additional resources, Urban Health Plan has dramatically increased their HIV testing offer rate and testing completion rate. As a result of their QI processes, they are continually addressing challenges and identifying solutions.
Tune in tomorrow for our final daily conference highlights post about today’s closing activities.
HIV.gov team members Aisha Moore and Michele Clark contributed to this post. We would also like to thank Steve Holman for his significant contributions to the content of the USCA blog posts and all of his work reporting on the National HIV/AIDS Strategy on behalf of HIV.gov.